Business Context and Reporting Period
This is an Amendment No. 1 to a Form 8-K filed by AdventRX Pharmaceuticals, Inc. (not Savara Inc.) on February 2, 2010. The filing supplements a report originally filed on January 26, 2010, regarding the departure of directors or officers and compensatory arrangements. The company is a Delaware corporation headquartered in San Diego, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific executive compensation event.
Material Changes
The material change reported is the finalization of stock option grants to the company's remaining employees and named executive officers (NEOs), Brian M. Culley and Patrick L. Keran. While the Compensation Committee initially granted these options on January 20, 2010, they were contingent upon a waiver from the company's Rights Agreement (dated July 27, 2005). On February 2, 2010, the executed waiver was delivered, making the grants effective.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or general management commentary regarding business operations. The specific details of the compensation arrangement are as follows:
- Grant Date: February 2, 2010
- Recipients: Brian M. Culley and Patrick L. Keran
- Shares Granted: 1,600,000 shares of common stock per NEO
- Exercise Price: $0.32 per share (based on the closing price on February 2, 2010)
- Plan: 2008 Omnibus Incentive Plan
Important Facts for Investor Verification
- Verify the company name is AdventRX Pharmaceuticals, Inc., as the input metadata referenced "Savara Inc."
- Confirm the total dilution impact of 3,200,000 new shares (1.6M per executive) at an exercise price of $0.32.
- Review the terms of the Rights Agreement (July 27, 2005) to understand the restrictions that necessitated the waiver.
- Note that the company had only two remaining employees who were also NEOs at the time of this filing.